134 related articles for article (PubMed ID: 16527836)
1. The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.
Frelin L; Brenndörfer ED; Ahlén G; Weiland M; Hultgren C; Alheim M; Glaumann H; Rozell B; Milich DR; Bode JG; Sällberg M
Gut; 2006 Oct; 55(10):1475-83. PubMed ID: 16527836
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.
Brenndörfer ED; Brass A; Söderholm J; Frelin L; Aleman S; Bode JG; Sällberg M
Gut; 2012 Apr; 61(4):589-96. PubMed ID: 21813471
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.
Brenndörfer ED; Weiland M; Frelin L; Derk E; Ahlén G; Jiao J; Bode JG; Sällberg M
Hepatology; 2010 Nov; 52(5):1553-63. PubMed ID: 20886569
[TBL] [Abstract][Full Text] [Related]
4. Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
Brenndörfer ED; Brass A; Karthe J; Ahlén G; Bode JG; Sällberg M
J Immunol; 2014 Feb; 192(4):1671-80. PubMed ID: 24442435
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo.
Bansal R; Frelin L; Brenndörfer ED; Storm G; Prakash J; Sällberg M
PLoS One; 2015; 10(6):e0128466. PubMed ID: 26030283
[TBL] [Abstract][Full Text] [Related]
6. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.
Ahlén G; Derk E; Weiland M; Jiao J; Rahbin N; Aleman S; Peterson DL; Pokrovskaja K; Grandér D; Frelin L; Sällberg M
Gut; 2009 Apr; 58(4):560-9. PubMed ID: 18689426
[TBL] [Abstract][Full Text] [Related]
7. Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
Levander S; Holmström F; Frelin L; Ahlén G; Rupp D; Long G; Bartenschlager R; Sällberg M
Gut; 2018 Aug; 67(8):1525-1535. PubMed ID: 28646094
[TBL] [Abstract][Full Text] [Related]
8. HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice.
Kawamura H; Govindarajan S; Aswad F; Machida K; Lai MM; Sung VM; Dennert G
Hepatology; 2006 Oct; 44(4):936-44. PubMed ID: 17006910
[TBL] [Abstract][Full Text] [Related]
9. Induction of high-molecular-weight (HMW) tumor necrosis factor(TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappaB-dependent activation.
Hassan M; Selimovic D; Ghozlan H; Abdel-Kader O
Cell Signal; 2007 Feb; 19(2):301-11. PubMed ID: 16916598
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a novel triple-transgenic mouse: conditionally and liver-specifically expressing hepatitis C virus NS3/4A protease.
Lan HY; Zhao Y; Yang J; Sun MN; Lei YF; Yao M; Huang XJ; Zhang JM; Xu ZK; Lü X; Yin W
Mol Biol Rep; 2014 Nov; 41(11):7349-59. PubMed ID: 25200433
[TBL] [Abstract][Full Text] [Related]
11. Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA.
Yu H; Babiuk LA; van Drunen Littel-van den Hurk S
Vaccine; 2007 Feb; 25(10):1701-11. PubMed ID: 17240490
[TBL] [Abstract][Full Text] [Related]
12. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.
Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sallberg M
J Infect Dis; 2005 Dec; 192(12):2112-6. PubMed ID: 16288375
[TBL] [Abstract][Full Text] [Related]
13. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity.
Yao M; Lu X; Lei Y; Yang J; Zhao H; Qiao Q; Han P; Xu Z; Yin W
PLoS One; 2016; 11(3):e0150894. PubMed ID: 26943641
[TBL] [Abstract][Full Text] [Related]
14. Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination.
Ahlén G; Holmström F; Gibbs A; Alheim M; Frelin L
Gene Ther; 2014 Aug; 21(8):739-50. PubMed ID: 24871581
[TBL] [Abstract][Full Text] [Related]
15. The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo.
Kriegs M; Bürckstümmer T; Himmelsbach K; Bruns M; Frelin L; Ahlén G; Sällberg M; Hildt E
J Biol Chem; 2009 Oct; 284(41):28343-28351. PubMed ID: 19674968
[TBL] [Abstract][Full Text] [Related]
16. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.
Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
Gene Ther; 2004 Mar; 11(6):522-33. PubMed ID: 14999224
[TBL] [Abstract][Full Text] [Related]
17. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo.
Frelin L; Alheim M; Chen A; Söderholm J; Rozell B; Barnfield C; Liljeström P; Sällberg M
Gene Ther; 2003 Apr; 10(8):686-99. PubMed ID: 12692597
[TBL] [Abstract][Full Text] [Related]
18. Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.
Chen A; Ahlén G; Brenndörfer ED; Brass A; Holmström F; Chen M; Söderholm J; Milich DR; Frelin L; Sällberg M
J Immunol; 2011 May; 186(9):5107-18. PubMed ID: 21430225
[TBL] [Abstract][Full Text] [Related]
19. Distinct antiviral signaling pathways in primary human hepatocytes and their differential disruption by HCV NS3 protease.
Jouan L; Melançon P; Rodrigue-Gervais IG; Raymond VA; Selliah S; Boucher G; Bilodeau M; Grandvaux N; Lamarre D
J Hepatol; 2010 Feb; 52(2):167-75. PubMed ID: 20006398
[TBL] [Abstract][Full Text] [Related]
20. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein.
Mansilla C; Gorraiz M; Martinez M; Casares N; Arribillaga L; Rudilla F; Echeverria I; Riezu-Boj JI; Sarobe P; Borrás-Cuesta F; Prieto J; Lasarte JJ
J Hepatol; 2009 Sep; 51(3):520-7. PubMed ID: 19596480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
